MTNB — Matinas BioPharma Holdings Income Statement
0.000.00%
Last trade - 00:00
- $44.87m
- $31.14m
- $1.10m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.09 | 0.158 | 0.033 | 3.19 | 1.1 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 18 | 23.3 | 23.4 | 24.3 | 24.4 |
Operating Profit | -17.9 | -23.1 | -23.4 | -21.1 | -23.3 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -17.4 | -22.4 | -23.3 | -21 | -22.9 |
Provision for Income Taxes | |||||
Net Income After Taxes | -17.4 | -22.4 | -23.3 | -21 | -22.9 |
Net Income Before Extraordinary Items | |||||
Net Income | -17.4 | -22.4 | -23.3 | -21 | -22.9 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -18.3 | -23.2 | -23.7 | -21 | -22.9 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.133 | -0.123 | -0.119 | -0.113 | -0.108 |